0001070081-20-000062.txt : 20200302 0001070081-20-000062.hdr.sgml : 20200302 20200302161255 ACCESSION NUMBER: 0001070081-20-000062 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200302 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200302 DATE AS OF CHANGE: 20200302 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 20676937 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 8-K 1 a8k3220.htm 8-K Document
false0001070081 0001070081 2020-03-02 2020-03-02


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 2, 2020
PTC THERAPEUTICS, INC.
(Exact Name of Company as Specified in Charter)
Delaware
 
001-35969
 
04-3416587
(State or Other Jurisdiction
of Incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
100 Corporate Court
 
 
South Plainfield,
NJ
 
07080
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (908) 222-7000
Not applicable
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.001 par value per share
PTCT
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company    ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o





Item 2.02.     Results of Operations and Financial Condition.
On March 2, 2020, PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this "Report") and is incorporated by reference into this Item 2.02.
Item 7.01. Regulation FD Disclosure.
The Company will host a conference call on March 2, 2020 at 4:30 PM eastern time, as previously announced. During this call the Company expects to review financial results for the quarter and fiscal year ended December 31, 2019, as well as other corporate highlights and updates. A slide deck containing highlights of the Company's financial results and corporate updates will be posted on the Company's website.

Directions on how to access the conference call and the slide deck are included in the press release furnished as Exhibit 99.1 hereto.

The information in this Report (including Items 2.02 and 7.01 and Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. All website addresses given in this Report or incorporated herein by reference are for information only and are not intended to be an active link or to incorporate any website information into this Report.

Item 9.01.
Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
 
Description
99.1
 
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PTC Therapeutics, Inc.
 
 
 
Date: March 2, 2020
By:
/s/ Emily Hill
 
Name:
Emily Hill
 
Title:
Chief Financial Officer



 EX-99.1 2 exhibit991pressrelease.htm EXHIBIT 99.1 Exhibit

EXHIBIT 99.1
ptctherapaeuticsfully_image1.gif

PTC Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides a Corporate Update

SOUTH PLAINFIELD, N.J. March 2, 2020 – PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the fourth quarter and full year ending December 31, 2019.

“2019 was a year of outstanding execution for PTC. I’m proud of the progress made in every area of the business,” said Stuart Peltz, Ph.D., CEO of PTC Therapeutics. “We’ve significantly expanded our rare disease portfolio, strengthened our global commercial engine and added vital gene therapy manufacturing capabilities, all while delivering on our revenue guidance. The innovation in our diverse, multiplatform pipeline continues to create value for stakeholders.”

Key Fourth Quarter and Other Corporate Highlights:
 
Expanding commercial footprint including continued revenue growth
•
Total revenue for the full year 2019 was $307 million. The Duchenne muscular dystrophy (DMD) franchise, consisting of Translarna™ (ataluren) and Emflaza® (deflazacort), continues to grow with 2019 revenue of $291 million.
•
PTC continues to leverage its strong Latin American infrastructure to support the launch of multiple products. In 2019, Translarna received approval from the Brazilian health regulatory authority (ANVISA) for ambulatory nmDMD patients 5 years and older. In addition, Tegsedi (inotersen) received ANVISA approval for the treatment of stage 1 or 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). In 2019, PTC established an early access program for patients with Familial Chylomicronemia Syndrome (FCS) in Latin America. PTC anticipates filing for approval of Waylivra® (volanesorsen) for the treatment of FCS from ANVISA in 2H 2020.
•
Real-world data from the Translarna STRIDE registry demonstrated that boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) treated with Translarna and standard of care, preserved the ability to walk for 3.5 years longer than compared with those in a matched natural history cohort. Importantly, pulmonary function was also preserved in those treated with Translarna.
•
A recent publication on Emflaza adds to the growing body of evidence showing its relative benefit and supports the advantage of switching from prednisone to Emflaza. The data in the publication demonstrated that patients treated with Emflaza had better ambulatory function and were able to walk longer, had a lower risk of scoliosis, greater percentage lean body mass and lower weight than patients treated with prednisone.

Positive pivotal trials for risdiplam support planned global launch in broad range of SMA patient types


•
Following the U.S. Food and Drug Association’s (FDA) acceptance of the New Drug Application (NDA) for risdiplam, a Prescription Drug User Fee Act (PDUFA) date for risdiplam has been set for May 24, 2020.
•
Roche’s Marketing Authorization Application (MAA) filing with the European Medicines Agency (EMA) for risdiplam is expected mid-year 2020.
•
Data from part 2 of the FIREFISH trial will be presented during the American Academy of Neurology (AAN) 2020 Annual Meeting, from April 25 to May 1, 2020.

PTC gene therapy platform continues to make progress with regulatory filings and long-term lease of manufacturing facility
•
In January 2020, the EMA accepted the MAA for the potential approval of PTC-AADC for the treatment of Aromatic l-amino acid decarboxylase (AADC) deficiency. PTC expects the Committee for Medicinal Products for Human Use (CHMP) opinion by year end 2020.
•
PTC expects to submit a Biologics License Application (BLA) to the FDA in 2Q 2020.
•
PTC continues to anticipate that more than 300 global, addressable AADC patients will be identified by launch.
•
In 2019, PTC leased a state-of-the-art biologics manufacturing facility with supporting research and operations buildings in N.J. PTC expects manufacturing at this facility to begin in 2020.

Continued progress with PTC’s multi-platform, multi-product pipeline
•
The Phase 2 STAR trial in patients with nonsense mutation aniridia evaluating the effect of ataluren did not meet its primary endpoint of Maximum Reading Speed as measured by MNREAD. The results did show a trend in favor of ataluren and the results will be discussed with experts in the coming weeks, after which a decision will be made on a path forward for the program in this indication.
•
Topline data from the U.S. study to assess dystrophin levels in subjects with nmDMD after treatment with ataluren are expected in 2Q 2020.
•
In 2019, PTC declared a development candidate in its Huntington’s Disease program. The compound is currently in GLP safety toxicology studies and PTC expects to initiate a clinical trial by the end of the year. The Huntington’s Disease program was developed through PTC’s alternative splicing platform.
•
In 2020, PTC plans to initiate three clinical trials in two compounds that regulate inflammation and oxidative stress from its Bio-e (redox) platform. PTC acquired the Bio-e platform through an acquisition of assets from BioElectron Technology Corporation in 2019.
o
Potential registrational trial of PTC743 in patients with Mitochondrial Epilepsy (MEDS) expected to begin in 2Q 2020. MEDS is estimated to affect 5,000-6,000 patients in the U.S. and E.U. combined.
o
Potential registrational trial of PTC743 in patients with Friedreich Ataxia (FA) expected to begin in 3Q 2020. This is anticipated to be complementary to PTC-FA, a gene therapy candidate for the treatment of FA, which is expected to enter the clinic in 3Q 2020. FA is estimated to affect 25,000 patients worldwide.
o
PTC857 will enter into a Phase 1 healthy volunteer study in 3Q 2020. The first indication for PTC857 is planned to be GBA Parkinson’s disease based on strong pre-clinical rationale. This condition affects approximately 50,000-90,000 patients in the U.S.
•
Additional updates on PTC’s platforms and pipeline will be provided at PTC’s Analyst Day on June 16, 2020.




Fourth Quarter and Full-year 2019 Financial Highlights:
•
Total revenues were $96.5 million for the fourth quarter of 2019, compared to $86.3 million for the fourth quarter of 2018. Total revenues were $307 million for the full year 2019, compared to $264.7 million for the full year 2018.
•
Translarna net product revenues were $48.4 million for the fourth quarter of 2019, compared to $56 million for the fourth quarter of 2018. Translarna net product revenues were $190 million for the full year 2019, compared to $171 million for the full year 2018.
•
Emflaza net product revenues were $32.7 million for the fourth quarter of 2019, compared to $29.8 million for the fourth quarter of 2018. Emflaza net product revenues were $101 million for the full year 2019, compared to $92 million for the full year 2018.
•
GAAP R&D expenses were $81.8 million for the fourth quarter of 2019, compared to $53.6 million for the fourth quarter of 2018. GAAP R&D expenses were $257.4 million for the full year 2019, compared to $172 million for the full year 2018. The increase in R&D expenses reflects costs associated with advancing the gene therapy platform, increased investment in research programs, advancement of the clinical pipeline and the upfront $10M payment for the acquisition of the BioElectron assets.
•
Non-GAAP R&D expenses were $76.2 million for the fourth quarter of 2019, excluding $5.6 million in non-cash, stock-based compensation expense, compared to $49.7 million for the fourth quarter of 2018, excluding $4 million in non-cash, stock-based compensation expense. Non-GAAP R&D expenses were $236.6 million for the full year 2019, excluding $20.8 million in non-cash, stock-based compensation expense, compared to $155.9 million for the full year 2018, excluding $16.1 million in non-cash, stock-based compensation expense.
•
GAAP SG&A expenses were $63.5 million for the fourth quarter of 2019, compared to $48.7 million for the fourth quarter of 2018. GAAP SG&A expenses were $202.5 million for the full year 2019, compared to $153.6 million for the full year 2018. The increase in SG&A expenses was primarily due to continued investment to support our commercial activities.
•
Non-GAAP SG&A expenses were $57.7 million for the fourth quarter of 2019, excluding $5.8 million in non-cash, stock-based compensation expense, compared to $44.2 million for the fourth quarter of 2018, excluding $4.5 million in non-cash, stock-based compensation expense. Non-GAAP SG&A expenses were $181.2 million for the full year 2019, excluding $21.3 million in non-cash, stock-based compensation expense, compared to $136.4 million for the full year 2018, excluding $17.2 million in non-cash, stock-based compensation expense.
•
Change in the fair value of deferred and contingent consideration was $12.4 million for the quarter ended December 31, 2019, compared to $19.3 million for the quarter ended December 31, 2018. Change in the fair value of deferred and contingent consideration was $48.4 million for the year ended December 31, 2019, compared to $19.3 million for the year ended December 31, 2018. The change is related to the fair valuation of the potential future consideration to be paid to former equity holders of Agilis, as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.
•
Net loss was $77.7 million for the fourth quarter of 2019, compared to net loss of $48.3 million for the fourth quarter of 2018. Net loss was $251.6 million for the full year 2019, compared to net loss of $128.1 million for the full year 2018.


•
Cash, cash equivalents, and marketable securities was $686.6 million at December 31, 2019, compared to $227.6 million at December 31, 2018.
•
Shares issued and outstanding as of December 31, 2019 were 61,935,870.

PTC Reaffirms Full Year 2020 Guidance as Follows
•
PTC anticipates full year DMD franchise net product revenues to be between $320 and $340 million.
•
PTC anticipates GAAP R&D and SG&A expense for the full year 2020 to be between $610 and $640 million.
•
PTC anticipates Non-GAAP R&D and SG&A expense for the full year 2020 to be between $545 and $575 million, excluding estimated non-cash, stock-based compensation expense of approximately $65 million.


Non-GAAP Financial Measures:
In this press release, the financial results and financial guidance of PTC are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. In particular, the non-GAAP financial measures exclude non-cash, stock-based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater transparency into the historical and projected operating performance of PTC and the company's future outlook. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. Quantitative reconciliations of the non-GAAP financial measures to their respective closest equivalent GAAP financial measures are included in the table below.




PTC Therapeutics, Inc.
Consolidated Statements of Operations
(In thousands, except share and per share data)
 
 
Three Months Ended December 31,
 
Twelve Months Ended December 31,
 
 
2019
 
2018
 
2019
 
2018
Revenues:
 
 
 
 
 
 
 
 
Net product revenue
 
$
81,407
 
 
$
85,833
 
 
$
291,306
 
 
$
263,005
 
Collaboration and grant revenue
 
15,052
 
 
505
 
 
15,674
 
 
1,729
 
Total revenues
 
96,459
 
 
86,338
 
 
306,980
 
 
264,734
 
Operating expenses:
 
 
 
 
 
 
 
 
Cost of product sales
 
3,542
 
 
3,761
 
 
12,135
 
 
12,670
 
Amortization of acquired intangible asset
 
7,973
 
 
6,062
 
 
27,650
 
 
22,877
 
Research and development (1)
 
81,831
 
 
53,647
 
 
257,452
 
 
171,984
 
Selling, general and administrative (2)
 
63,497
 
 
48,666
 
 
202,541
 
 
153,548
 
Change in the fair value of deferred and contingent consideration
 
12,400
 
 
19,340
 
 
48,360
 
 
19,340
 
Total operating expenses
 
169,243
 
 
131,476
 
 
548,138
 
 
380,419
 
Loss from operations
 
(72,784
)
 
(45,138
)
 
(241,158
)
 
(115,685
)
Interest expense, net
 
(5,463
)
 
(3,248
)
 
(12,491
)
 
(12,554
)
Other expense (income), net
 
11,214
 
 
(937
)
 
13,723
 
 
129
 
Loss before income tax expense
 
(67,033
)
 
(49,323
)
 
(239,926
)
 
(128,110
)
Income tax (expense) benefit
 
(10,644
)
 
993
 
 
(11,650
)
 
29
 
Net loss attributable to common stockholders
 
$
(77,677
)
 
$
(48,330
)
 
$
(251,576
)
 
$
(128,081
)
 
 
 
 
 
 
 
 
 
Weighted-average shares outstanding:
 
 
 
 
 
 
 
 
Basic and diluted (in shares)
 
56,570,002
 
 
50,331,914
 
 
58,863,185
 
 
46,576,313
 
Net loss per share—basic and diluted (in dollars per share)
 
$
(1.37
)
 
$
(0.96
)
 
$
(4.27
)
 
$
(2.75
)
 
 
 
 
 
 
 
 
 
(1) Research and development reconciliation
 
 
 
 
 
 
 
 
GAAP research and development
 
$
81,831
 
 
$
53,647
 
 
$
257,452
 
 
$
171,984
 
Less: share-based compensation expense
 
5,645
 
 
3,986
 
 
20,836
 
 
16,096
 
Non-GAAP research and development
 
$
76,186
 
 
$
49,661
 
 
$
236,616
 
 
$
155,888
 
 
 
 
 
 
 
 
 
 
(2) Selling, general and administrative reconciliation
 
 
 
 
 
 
 
 
GAAP selling, general and administrative
 
$
63,497
 
 
$
48,666
 
 
$
202,541
 
 
$
153,548
 
Less: share-based compensation expense
 
5,821
 
 
4,492
 
 
21,298
 
 
17,156
 
Non-GAAP selling, general and administrative
 
$
57,676
 
 
$
44,174
 
 
$
181,243
 
 
$
136,392
 



PTC Therapeutics, Inc.
Summary Consolidated Balance Sheets
(in thousands, except share data)
 
 
December 31, 2019
 
December 31, 2018
Cash, cash equivalents and marketable securities
 
$
686,563
 
 
$
227,586
 
Total Assets
 
$
1,623,782
 
 
$
1,119,222
 
 
 
 
 
 
Total debt
 
$
313,859
 
 
$
153,014
 
Total deferred revenue
 
11,657
 
13,438
 
Total liabilities
 
$
1,029,452
 
 
$
768,495
 
 
 
 
 
 
Total stockholders' equity (61,935,870 and 50,606,147 common shares issued and outstanding at December 31, 2019 and December 31, 2018 respectively)
 
$
594,330
 
 
$
350,727
 
Total liabilities and stockholders' equity
 
$
1,623,782
 
 
$
1,119,222
 
 
 
 
 
 


PTC Therapeutics, Inc.
Reconciliation of GAAP to Non-GAAP Projected Full Year 2020 R&D and SG&A Expense
(In thousands)
 
 
Low End of Range
 
High End of Range
Projected GAAP R&D and SG&A Expense
 
$
610,000
 
 
$
640,000
 
Less: projected non-cash, stock-based compensation expense
 
65,000
 
 
65,000
 
Projected non-GAAP R&D and SG&A expense
 
$
545,000
 
 
$
575,000
 
 
 
 
 
 


Today's Conference Call and Webcast Reminder:
Today's conference call will take place at 4:30 pm ET and can be accessed by dialing (877) 303-9216 (domestic) or (973) 935-8152 (international) five minutes prior to the start of the call and providing the passcode 1732477. A live, listen-only webcast of the conference call can be accessed on the investor relations section of the PTC website at www.ptcbio.com. The accompanying slide presentation will be posted on the investor relations section of the PTC website. A webcast replay of the call will be available approximately two hours after completion of the call and will be archived on the company's website for 30 days following the call.

About PTC Therapeutics, Inc.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.

For More Information:
Investors:
Alex Kane
+1 (908) 912-9643
akane@ptcbio.com



Media:
Jane Baj
+1 (908) 912-9167
jbaj@ptcbio.com

Forward Looking Statements:
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this release, other than statements of historic fact, are forward-looking statements, including the information provided under the heading "Full Year 2020 Guidance", including with respect to (i) 2020 net product revenue guidance and (ii) 2020 GAAP and non-GAAP R&D and SG&A expense guidance, and statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and manufacturing capabilities; advancement of PTC's joint collaboration program in SMA, including any potential regulatory submissions, commercialization or royalty or milestone payments; PTC's expectations with respect to the licensing, regulatory submissions and commercialization of its products and product candidates; PTC's strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.
PTC's actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC's products or product candidates that PTC commercializes or may commercialize in the future; expectations with respect to PTC's gene therapy platform, including any potential regulatory submissions and potential approvals, manufacturing capabilities and the potential financial impact and benefits of its leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that PTC may be obligated to make; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions and potential commercialization with regards to risdiplam; PTC's ability to complete a dystrophin study necessary to support a re-submission of its Translarna NDA for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) to the FDA, and PTC's ability to perform any necessary additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC's ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC's ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD


followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the commercialization of Tegsedi and Waylivra; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC’s products and product candidates; PTC's scientific approach and general development progress; PTC's ability to satisfy its obligations under the terms of the lease agreement for its leased biologics manufacturing facility; PTC's ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC's cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the "Risk Factors" section of PTC's most recent Quarterly Report on Form 10-Q and Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC's other filings with the SEC. You are urged to carefully consider all such factors.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or risdiplam.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.


 EX-101.SCH 3 ptct-20200302.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 ptct-20200302_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 ptct-20200302_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 ptct-20200302_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cover page [Abstract] cover page [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Address, State or Province Entity Incorporation, State or Country Code Contained File Information, File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 ptct-20200302_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 ptctherapaeuticsfully_image1.gif begin 644 ptctherapaeuticsfully_image1.gif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end EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001070081-20-000062-xbrl.zip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�,FHP#YVQEW8<[,Y4!_O 76 M3I("UL-/&)DFW $N8DTD+*R3+VZH7&"N[G/PN8@9Q ,.XX%+@68AK#4/&((2 MANO''!J*@'U3PX?<4#=A$B$ G&LV T$#;32S9=Z,SZHI??_%YNOTVV^XO 6M M]2L\X^)ST>$KDF_-^'_ZP>RUCLHTHE/)\)(9%IPT$2(. /XQP-IVD_2R0JZS MX(50W,:SYS$A9N=.0AN$!MO-_8N /E MM^\P.0NPU.(#8UD;(#N16PZB35(X6P"@S1MK:"X(O08_$N]O)>]I%JP "Z+A MMH0-%\U!<)$)![,=.0J8YA,8'CX9@R8!@34"?,87AQD@2N#5D2&WJ MS5W!'0&"B^S/1E=7%P<%\N&RL0CYCT@9I9R,#M!0NOXV>-@&R 46L?!&=@[^ MJ_1(YRC!;ZE[+5'>;F9RT@71SQ#V(%S 8@^@@;0;$+R1#!U0\')C&P603T$7 M@ @TO*7EN <(Y!8GFH&*3'#[TG+DP?9=T$=(2'A#RWYGQJ9PVQTX &"A\!W M[&B/S$(V^7GOA^<.["EMOP\24-2V_"DG,]U,,0'/I/X)FB[29$-61I,>M3%F MH)#=&0;8?9N1:*8NH#D7,K",P)PA8^:S"8^5D%"V6Z0D@G,#O(I6#)HSP'C@ M0:&.1]$&'.KX/!*^-/G202AO3,H_R;=@["WFND;EP%+I3H6S_B!3&:F\7@UW-B(6IYGW"K=53NB\"\," X MX#!#C@RJ_ &ON8!S4R]T1^.)C$#<-X*:>">!T' H "V@4!?3+\U&VS"2> M!RQ:F?*=?&KV<19FDPD 3XTQ(.2Z02< LT/JWM)YM/=08E:KJ9VW <^$ZRKY MBJ+O]^9EDYP)X4A1.J=S8G4,[;C4!;07 DSV'(WG-+QF,C8Z4A&5OQ3PED!X M/D(0*H<_=0$8.<7@!JK0<^9P&S.&9#0%HP.0 TPB6YG,._MX<7KV\?)7I<@!6ZX+TDEY@SY"Q5'Y4[PW#T". M; J6I;1S/V.$S153C *./A^HHHB1[R?0V#F3N#;2($T0293Y5X M]3:XKHZ7T]IYHGDI:NS1ZT)E@900A5"M$AR9@0UX!P/)0^L[DKIO.5,.GU14 MHHKION6(I2Q6**4,>*3 :K-*EH\^^2]P6TSD&,,)N&8_%U[B+HGNVQ MX83'U+X&-SOQG4;J]$_D?UD(P)+_P3SW-PP\XYS 9 //W.:H1E7(72E-Y9X? M"\_CX!XKFRY5NT"4+VF"1?[\:P(P1W.0[!__>O[E@(B ^ZC%Q_.\SDJ)OGKH MW3L\5UJ]^UV*&I<0A(FZL8=Q'_*!H];$8LY/W)91YR5[[\.GT<%&*,XY0X;# MOJT0*PUM@;!YD MD:4PC,L!L(F$^!@]'.RFD7B@'OC"]")C,4RS1>$W$,G"^S\0'#E%9W3 MK]Q+/'+!J*RQO0P82B! )LBB)%3ZZ/SSQ>GH1*7TLIT;V#KF$$%:85V\3,]/ MZ(T(E\: TBTCQ2%Q[!J"^"$BLSEB$)H&'L#BR5H7 K?IA:0DR8N]3R:5PV?P F!?275D+'8?C.[=VRE>#NF;Y3F^Y%F+M.Z7JJ,L4EFK,AC]3GO5 M#SCGL;!GPG?DC:G)Y<'"NECRSS,S ^^12?8H!O,_O8TJ=Z%K MM%JM1@__7?28&N'2)I+;GIJ_-Y'3QD @IW1&LP9I64!Z%G+FA S=M%$,;B4E M^UAJM!:=[0R=5](GBPJ!W/1&*=M=AB:2W 0C9'KO;(1%3DN)YX7]M'XS!CRA M?,=BH0DT)T\!4.ZF5"Y+PSH;W<96V2A/T"1:28Z5ZT.;D1+IC&C(6I2[F,=\ I#Z.X$(C(CF; U@%U676J8H-?/HS( M%QI>4'(&KFME+$N2]G,!@6BK!2%Y4AES[]*C(/K MT&U)=3!LW:L/R@9Q;8YO?SM%NN\1\*..<(D07D67+3.!E2N9GRNQ*-&2A_@X MF#XH/C:")N> ^Q,ZQQ;_F< S9L]X@^@]Q8Q+'PL(VO*T-: ME;PE'.3V,ROWG"_5F*\Y7ZIP$(=.HU1,5BV=$Q&I+4!OAKUF-SNJX+[SI< N M5'&Y?/\B*-LW@UZS_;0G!Z!1U_5=.([BGF,K[G1I]3K-1QX9:*U; R0O-NCZ M+,X.1K@+K\Z@V=D,VMW>TX']I*&8P];SD&[V38WSVN,\V]#Y ++:UCJ)^!20 M6\/FX,DP?\)(S-8CD+T[@*&E(5Y[B/\R>A%S]1+S@ZD0$G/\H1-3"?BM 5 M =YN/EV$/S0$J]M?IT0>%MV/XCH]BQ"/$U0G0*ST'K*)*V,.MH@P\I#N?\PJ M0.0&AW1C%U]QOXL_,9#G-7O-=?PR3W, MS;YFIQJ^Z18X&\#L0S)(\1Q&KWU@FM.Z*F,!*K51"/WT(*L]MM#A^164L]F[VFN2$9-.=7GO,E MR"]_D2@?W45YK[UIO ')!I;[>HGA$K:\9 ,T*2X& MQ$GD^2N+DUH+BKIP'B">4UPX[)7:,;^11R!K;JH^-^5JXSXT@X7Z= ]P29%N M1WMT.D]5Y'<4:8$'-U6E]]'$!-?A$2O\CBXU"\',;]*EH,4?<1CNZ-)^8:1: MEVKN7[K_>"9/5TJ3RA/*P_3T>> HATU8*"MD?2?5(5-9(HOG-#OI'B9U\+-I MK0%EQIQ,OC]@Y7T1=X$]7!/N?[@)T(A;&O_:4&ZV"WO3P3_P?*K+[73TZ9EO MJK&EB="BH[O89S])Y)F^RS-1%0H!O@0"/J*/CI0#=SF>D_0= G+G_92[>-*: M?$F%V@FB7E,1$G@ SY*4(0!U6UJL8[M"^?EDE$R3*%ZB?K2&_%),IN:'VG$" M0L?%TS&S">&>$Y'(PT-0')&)*VX7;R )P)%/S[>+05BH)4Q[0XL&.(?B&Q;D M.?^+PB!X*O'D:4O:=JF!]/K,8@+(5&;OF_YS#)4B^_I9,WBT.HB"IZ<=EP=@ M=-CW]FQ:@^8W9V7T*7B:6^[3]=+JD\(6M0((:BPH,Z1L]>3Q8G*-(V8G MH73_%*I[@V+J8Q;'>-07_S+>VO?>K7:U6,R:^K9X-=,#J9<"P2++[YSVJ17]+75^&"J%,R M(UV753%.7'DC1&Y1X';9_ 4\ZW/ORJD8L_@6#R-]TP;,("^_:7?RBA,MS>N' MH:5$$P+B;J1LK?T*X+F#IYZ9XJFG\51G/*TD+[\!4]U.5V&JV\\CP,60Z")< M\/18J-Q)NK0]XTVO^V3 EM5*V0TC:?LF48ZV16'ZN3I@Y6Y9^BN/7>['E@>E M!'*?=,CDH53J3,[5]_?*%_7FOV:O)LW>_(I'7^3;0?"U,+8M0G6'*OJQ94!. M;OD/.;01N,"96/P34C=]:5409Z]^8>1WG^.WRUAR\#X25+V93[VW/8O1^1FQ M%R-+3[-1;QK#DX:Y?&^.FM8#]Z=,S)Z5S+F:L>CA5I<((\.BB]V.,I2Z^DC^ M$F4\X &;'3.;)G@T$/7I5#V98+XH?K3WVQGSTT-.I&>$1TBH\^?F^#T_+4QN M^F2^HZBVZ. M@^;)36CC>4HP'&'VR@[Y9C0, ^#9XG(S'BZG>M60K/22&Y1"\:?:])E.#-'& M0HQ6+V$UK063@05_CN-0(6]P(ETAK@LYNGLFB6N_J@OF4#31FX+$U2^Z3WJ,37GP'66%8CVPYO7=7[-.5VYTM:_>^Y;SP M_(KU)Y_G/@H#^;W8@8\,X^:+!3:<6LV]+9K'=T;KT7#*?34\FL0B^R&4 Y*_ M*'O9;,'DQ\!'+,0SF%T:1.PP^[""MX71#;? "/V?]\S^WOU&=K:=^L>"2;Y\ MS=SL4FOK+>K.[GVLN+#%=7_ 1UD63(#U(OB+WU/I5OQ)8=12#%+@N8=8=/!< M(3&X/P!W):NG60)SB@S0W_;]0OLEAG0,BDNX\IR&U(!3>AUTV6_YZ:0O-\*] M]_O2SA5)!(H_DLX:F)HDPABR,AMP^[[\AD?%'=SG<#WHCBM8?!<8">@*$]B' M,^Z N'Z&QERC:C)'?O7-\ _[\=697RX0[I4'WW&N:QY9!?Q2Q\LVTK9X]$H> MM74.%V81.95E)/A?,6>BT5%?=-PR]^8./!Z!AI:0U9E?S@/M1W@@-<,SAR_X M2J3B)]FK4+=#B[07Z86L=%%.!L)TL\:.QLZ&V!EH[&CLO*#<*1T]-?!V#WCK MA-:3TMBO8$JOQJ*W0):]]Q=I8>GN7/+W&D-3:/=ZI5DRE6';]7GI]ESV^S9:QNM5KK%(FR5Q 9M=H=:W2YECKI=XT M^E\8_=V-5)^&_L[/3T,?!'^OW]'HU_/7W+&&.XR^5=[*,^TU/>XU;:4 :OE- M:5I5E@[[+R(,ACVCT]720*._;&O],OFUGM%N;U+!K]&_\_,K&?JW5DB^)=9H MMWK&<- J+6^4=X=""8BC&:N\C&7U.D:_7=[H1$D9JV;>V6_YH5C9&V?T1I7* MS[7J\]-K69WYZ;6LSOQJLY:/&Q$>#,)EU;$CCD4DW^J4;5>)J*N#O?>A_-46 M?UL^N]'M;%+O4H'%K?K\Z@#>?L^LY^)6?7Y/C@CM+'A-RS#;=2PUKL'\JB]Z M ;V]_B:A_EU?W=T)*FZG4'[D"9C=7_F[5ZG]WX2K$^]CZD\YGA>.;R"(:XB% M6NBIOC'LZ_VDE9Q?]<';,UH][=Y6];*/JRU\+YAZ8QJ"M0Z^5G%_UT=MM M&[U.'553#>97??1:W;[1V>B0@@HL;]7G5WWXFGW3& XV*6;>]>6MFV-PR5P7 MFC2R]T!+!X$Z'O=Y%(?JC;C[EO81*LKHO;;1&6HKJY+SJSYZ.P.CU],'-59R M?M5'K]6RC&Y'!V@J.;_JP]?L8EUR'=^3]ZHO6GVNF["=[08SZD\9X?@2;T8F ME(?DAKH)PV(CATU8B,5&Z#G8\"!TC9D%^!AQ)WW9> U14KXMTZ]3@MAIE?>T M :T"-?J_)_J'1KNCT:_17[:U?BGOO-W3Z-?SU]RA=<,VO:NR9&"V>%ZG6#D7 M1FO-$G!!V0Z9,GM#P^ILLM.C=/0JD\+5C%-YQFF;1J>_2:JH=/32C*,9YP7+ M,,&+,TM\ENZ.,D[=B:.Y[N%#4P8MHV.6]_SVD@*K9J[C)Q%%9!(*+W,?A:_= MQI>8:]G$Q7[?,OJO6*Z[-7I(1OEF[H:5:,GIH)M!,L#$3 M6!W3,+N:"UZ="TIJ(FL6V3?Q/9*#USO5;P=8I&:.U$<_9B&+XBSY9A!?GY56 MU;KE_:[1Z97EL+1JZT"-Y.^+Y+9AE:8 7R-9(_D;;#++Z S+LA5*0UE#^9N@ MW.V6Y>@$[4"\B /Q6PR_9]X#V>>^+3QVH-V(LN1W7Z/BR#0LL[RO@RQO:40% MYJ?1OS]L;W*J2/GHH:T]S0??5'=J]*WRUFN75PO48/Z:.TRKO"5NNHKMA7PG M6<4V9A,1X@$3Z#B1F'[-G"FM.'U8,GIH)M!,L'D]6WMH#*W7.^-13TM4 -1H%E%YZ:T(_69Q<3%_!2-XY"/DYB.7?"K!+"' MYPD?FA+V]4RXL.8U/7GA&=S0!FYP1((4+.GI+=O1*&]J0*FM'5S1-WH;O8!Z MUPBF758M9+20>:5$ZL!HM[_=YRD_P;20T4)&"YE72E1W3:.[A1-FRT^QLL1= MRD I+:->&T=:1CVO4J UV&2;]:Y1[#5+"5[0))HQ>:,Y6 IV53,W]()SS8/? M[5?8I:[76*^Q7F.]QGJ-]1IOGH;S8$ NJTXF[@])6>8T*$R43AF)9C1D$1%) M',74Q]X.2\H,=6* J@LVO99Z+?5:ZK6LZEQWRK PK6U8%A]HQ&T")@1QN)N MB8'G=Z7F14U388\7_Z4H>*&PX"O$2KL]H]MO&:V65=YHJ1;YF@>^*P^TC';; M-(9;.,9.\\ NSD_SP/ONP!CTVH:YT?LB:L\#=2" 9I+W'326>D;;_/9]=17$ MR$[Y5-O=-A&P4'E2/_TPL$SK:+S6UW*$Z]*P<'=-W:XR2(]"!<::/DI>WK.K MI-I:?4_S>:?N[BJ]=)VSEC):RKR6E&DUA\\J<]Y5>FDIHZ6,EC*O)64Z34O; M,M]5RI205%I(O3J2M)!ZAI"RFOUGQ85WE5[UVD[17@Z"53-U]()S?>'JF6]1 M.!H!&@$: 1H!U4' CE!"XV,#TZA:>4/Y[581=RQ<1V8T#L@%BQ@-[9E*&[(; MYHK 8]!PR&SAV]SE-.;"+ZF(K1;;E-!;K\[\]%I69WYZ+:LSO]JL9=T,CKWW MOXQ&7\".6&]@U!/M95SX5PEJO_QYXL]LV M>IU-3CRN+'JK/C_-G;O#G5:W;W2ZF^SYK"Q\JSX_S9Z[PYYFWS2&@TVVH^XZ M?.OGFW]B472H]@,UQC1B&(CQ\%V6,MQ/TO=:UA *F^\YK-#;F;I@17_[EMSJ MO:!)@[\&X&^#$OSVD^8U^'=P?AK\5LL8M#7Z-?IKB7ZS9[2>M_VN)NBOFX,D MORU72WT6?D-G-,N^%:,,+[;8C4T^I7AI2K]GF%LPMLM KU+PG98KI>06+5=> M^LRLH='K5>-53*7@.RU72LDM6JZ\='BDW3-ZIC98M&"I-KMHP?+2D:=NUQ@, M!EJP;#TP]8(2)MV[: V#*NQM+.1JLL^O99Z+?5:ZK6LZESK M9GNDQPI$C]L:]01^&3'P*H'DEY_KED+!O;;1&>H]S#6:G^;.W>'.SL#H]39) M %<6O56?G^;.W>%.JV49W8X^GJ=&\]/LN3OL:7;;P)Z;5#GL.GSKYZ;K$P;T M3KN'3A@86-]>GUV]C78:_#4 ?\?H##TM9"#*0+ 7CU&]C2E,./]=_BO_&8=+7]7'6;A8V2EKC$-&KQMT$K/PD+JW M=![M+=V^VE#VN,M]UD@W-)I6Z\?BL*UG3S1]0O94G.9#'19P:#,?9K"&UFN0 M+)'0RG#,?5@D];W8@2]"C[I+8#%;2LA*>]UI[\'@74SKZOF?85 M]UA$/K-;"@NFW6]VJ;_U%A^XU'O28\7I%XASC\0! M#'P73?T0C+<5R?UR=4RNX%X:L 3F%!GDHV\W[V6UEQC29>(!P.?D6/A2G-*8 M.>0#=:EO,W(Y8RR.7FY\>^_WN4_BF4@BZCM 'O;59D&LJH4(C(T>E/VL%VW MOLS^O/)E E,6>(&$T FSF3=F(6F;!K%:YE!CY<7G6E8LK*N@J%L.=>_],8UF M!K'A7\+^F_ ;ZL*"1#)?"MKNFBGC,6)V D]S%M63@4I0:E&Y8$'I";6MW:B# MGM'M?7L0L@3T*@77::E21F;14N6%BT"MOM$M\5O62BI5ZF;@K;&#KT1,73** MHI6 A9:[.YC1V(;@78,2G0S:G':FT;/:1G^@\T/:Z*LV!VGA4T+A8YI#P[*T M\*G$2?BMH#ZG*[_ 7$MUJJ%>8[W&VK'=- *B_%B'C?5[8TNSRJ\2 'SYN6XI MAMKA3715:4G7$['W-7U<-6(Q.LD1@F3 M&"UK:'2Z.HFA/>MJP.@,NUKTZ/SI;LA;G5O3:ZS76/NVFX0\ MHUC8US-0?"R,_B&W@,5SLM\SC6&[:PSZ+;D3K-LR>JV>87;Z^ H"3_AJGW%$ M>!0ES)'WB"2.8O@ @R0T)BL[+^5-*WOP"+02,!L/Y'3GZ[8LEX'WRF//EB'* M5O6='J\0<>P..T:[W=(A1\W^I8>\9O_MUX& ?NU;F^2;JL[^=;/*GI)QD(;4 M.K--B\^=#VGI:&#IHH%Z,Y>VW;3PT<+GE82/WLREDQ$[)7%UH%JOL5[C+0BO M>XY)SGI8.EVXM7RZ\*IO:FTE9?#TXXY+-R!]_O+W/7_9>J4CD?7YRW4Y?_F" MV<*WN 4;=D$6CI7-])]?=T+5<71BHC#+YYU6NU";MGM@R0 M9!J^]9F?9L\=8L].7=FS?M;&)Q9%AR3(;0X?W&Y;OCY"5J,TQC1B:+MZ:' H M)YW5V?AX\D[ZW>7^;DV9OP;ST^BM[.K6376MBV\O:;'[O>=:*[!*E>CHZJ;2 M53=U.YM*X/)1L!2LJ45/*?E'BY[RB9Z^%CVZK'*'Y*TNN=-KK-=X"\+K.665 M[<%J%>/3!S@*.777W/_DFL7J=;]&$U\)A\[_$9%CX4]8R'R;D6/JNM(-_X.- M;1K%Y()Y6'89'I)7)%PV4'LQ4!L'>LOAGYA>,Q*X%'ZD,>DV7>$QR)@PP,B0K(_[+W@'UA="VQ&/)<%N;V^;06R/N6C:PFMB MZ2$V*CR047,<<03F#XPY9!'S8Y5;D'2'S@,1Q1MVC7/.9A@R6+[Y$M&R'N@- MY:XLXJ4!$/$K]VC,@#CQK2 SD801H1-8&9GZ<%FQKYSV>5.A/0,BY\--IPBP MRJ@Q@;$#>@!K$7QV04QF*X:-W5^"63_),1J+)";/K%3]_F3" 7& !(ELCIS2 M<$)8<=\@4U>,*:" BV!&0P]D12(5;@8"6&X[*7"1PX%!057.#>*P&^:*P /P M*XDB/(^%-@J1O_)R6!OFANVY*%XFDD]C3I$W/.9P&R8>0;O ;4H0,,"CSR8\ MCE!L!-",?//[+8]G)*2A[%\Z(5$3B0P055O0YWB[F@OT5!P),JAP$CO&@X'D M%"8B\1TU0-FS)$64,JF<#?>!4J$8)Y&:&2P5],@G'(8=\(#A>DEN"JD?3;#( M/I9B+Y^1.GLH!$$81;(?D<]/B27\90S=-;C?L%V*/X2,RMXCR6V+J<^ GRFT M#E(M\3T6JVY@A7S&G.9K*I^R\=X9T.U< $@^^NFB"/^P3 /\F.J!Z/5&!1+* M95_)OZA_?XWY]Q_#_S+!CF@-P(XPK<:PUVF_XECH-=#B?R\4_XA=6]!4^XMW;[:4'T9]1PD&'U-'O@G+#GY0/\L#0N8 MO?XKCN7/,?WS(0ZH+U)!I=S2T"&?A+A&D_<2['PFM?03X=OM_7@W&F$.'HS$ M;S3T,;6OIR$:-KB93H2'/TSD?^@BSG@DG90(W0]&(^DQQ93[TM+ Z37<='I1 M/CUI<3_)DJD^J"H>XE(UOZ9^9P MV 6'QG6+3:?=@S$E.^#YP PBH+\0S3*_^ T!'>!XN0VF5 [-@B:@ONG=G@]8O"7F9O:J'C)-6Y &X3[/;I6I??SI27G^O!4C/64IITO(ID &-6A,FR3 M. &ZX&.V\D>!$N! ^E'F:LM1*P,3K.>CI5M79J;LZRG8X]@Z^#)S;"Q&4A8) M@DY"(&)IU[LXI 1N$N&<1,DXM7]5_Q[U$UP] T\9M,@/SWJB%#G!F.PUCGI(!;+N;4!1]"H,7NHHGF8RQB M+JE\E([F05HA^5UNPW+!4(R'J+#62T)_)W=3TK620++Q\%)P5E@^C B;6*+"*>)_>(\Q/A/=?BI M9#Q8-3!OD!)-\IODS@>$AD?G&%#@N!M9N4OCN6SS%IRVB.Q-%QRUA\ T]L@> MA5MM#OX.PV]C<*Y@B/@18TY>^K,B/G[">)/OX"?H#/_$-)PR>2E???R"P0WY M5R2NO-W./D2SQ4]P.U #/DO.XK#ZP/S0&8I+).D3??;7E_*I,PS<)<$?)2Z* M08"&E'PH@@#P7F>A,+#_: 1RPB!WG](N!>XZ8H^ M@ ._BF]1A<8HPUJ( @C2FYHR%DL@UDACZX5SA,868C* ,7 LMC& ^,DC)0D\=E4Q+S(LJ!M0)L'-(2! M (.#*Y8)PW\4.!#][Q4&5,$"#*0LA1?DW8C[Y:!#JCH5U[VPH%W<)$.#-]0% MTMXO?7/&7SRW$""PZO"0O"6/S*0"2ZIL!T-'KIAR.[K3!7Q2D9G5Y@LXQ,8* M@:0ET2EYDH(\7DCE3(8BWT[Q\4Q*+U8GE4%B[*))(L$C(7DD!\'\$/2)Z@J: MP34V4N1(GL'Q1#$0'+I:6 B@:N[H(7P$12D\X=^(A57%D^(0;0@9D *V=#@@SSM:C:VE863@ M,N+,00>) *U#G-L8*0V8@9'U*/I^,)//A M%//H%]X'5E$D#1\O2R?G)0:J%59[M[&2D M5G5E'JE$E 12#_TO2>#2\9K%A/Y2JX+ZOM([/KM%&LYM-T,\CBB5' V4^V1,7:6/EJ:U/.44 M1%'>(G(E8&#YMC4$5>R-U@[8" 70H@CB'N9')"1SFPVF)/\6N/]28KK5,0W$ M,#P))/R+06OFH.&!X)D9*JC$7L[XP "E<@ [8GF73.O>R4<%9>45V"UVS/<>2Z9,:9?5>9!LK5+;Z-8KE MDDFSA"([PQ-H]X3R/;<+W2(3!$C1&X!IQ!4 ]MX\D[LZYD'EO/,R#_#L!0YV%(+4OF#0JX,8SU-YFJ_%OV=5(*9[5R_\R MT!B[99CJCJ2V3X+4C)>^#R@*>1?^A5&K<2FF@MN $+DS MD2K.R]/C)OF/2&18*@%W5!J=-GR;)"H?"?(+T8&9=ZG'TFYWQKT7PJ#>VW^U&.Y/U8"!D$N>!:P%W*\8J0NX0U3B=O"R*1)(7.ZL-9% M.;_0_P8Y]28N_0L^ )8:H]')L9$I$2/7(%+&9Q;XS@#C:O90(+80ZL5UDM1. MZV52MKKA[!:8"\MZ:"XSD5'5YY70=6K4$T? (OLB=9-DI1,N$9B6N$**UY76 MO.'RL7G*>/>/%3T@-G%1^R_'4;"=@IJ5$55C$4Y%21,E7I JV2QLE841_E02 M+I(84E+$YJ&=>/AF(A3@P@;5(+6.JMAYA +LJ\V"&*D5XA'[H;*=0-N7K@QG MO2G[MZS*<2R<^?N_OWL[BSWW_?\'4$L#!!0 ( )N!8E"QI8@"N0, .<2 M 1 <'1C="TR,#(P,#,P,BYX=7>'EWTX#8UHH6,=@F M),8F/@1OR'5N6XO$SFRG+?]^MI,TZ0>E2=#$0R3G^I[C<^V;:SLGIXLX0C.0 MB@D^\().UT/ J0@9GPR\^UM\=GM^>>F=#@]./F'\^.WF"ET(FL; -3J70#2$ M:,[T%#V$H)[16(H8/0CYS&8$XPR$7&.APKZB4X@)(EI+-DHU_! ROH Q22,] M\%+^-R41&S,(C80([! K#I5N3>0$]#6)026$PL";:IWT?7\^GW<234=,=*B( M_"A;G"M!B7:ID*-<&%6H _D0:542X9*H8S1X MR*\GYSV$M)&0*CPA)*DOHPK,I.26MG*DB)JLSU8]CJNMH(8)LU50XYS9]5V] M(F<38M]P@DEB)/2LQ^-Q"HF/F,+'[QOZ2JJAWU5%C6@I$Z_%#+7W[ ?A<<,S- M3BH9W4]&%7F= =]133,ES654%^38O85[+D<%8 <^KC>D MJ9B)E/13RK4EU7:$-@=774H!LH[4"6-!I M?0E+E&NU%L'X#)0[:ASML^]M@>5M7%(T4\()H^K-;'T=E35;)ZIBU-(%=404 M&-O );BA )U(R_:U5EHL4:Z%2_RZ",*YT([)F@ICDC ^%IG%V.R^W2\V[QL8 M(W=@[^=;Y^YCO9](D8#4S!RG*C<.1S"5,!YX]MZ!BPO&$R51QUP$"I>- 5:/ M%6Z;,A":1BZ(JU)DP6 +]\!39K8CR"/_[T&%,*X;E($PSCYP3!$9U8W)0"#Z MH.$D$NJ&8R#*W-H;)9XEN#,.B)G;[KF8@?Q#)E#\:_"0[;^_N7SM/N[&WX05 M8Q2CE$DT[)K[LWD0+G]H8.08D*586D_\=>0:9ZH@_,V'KKT^ SDX=]D!7/MD M]\:M?A5;8;FQF."\K/EK=2TWK%0_5_OR7S&(C)26Q/X1T3(UZV?7R6;,DYNS MQ$S96>[AN1*>K^):!XM,SMM,RDA4:KJ83NV(/Z5(DX'G_J3TF8;80UG&9!9# MP?CDTMAM%":GG-5D-!/AG?,+4^FDN]S*XLGVAN'!/U!+ P04 " ";@6)0 M#_RMQ3H! " @ %0 '!T8W0M,C R,# S,#)?8V%L+GAM;)V236\"(1"& M[_X*2L\LNWK2N)K67DRV2:,Q>D5V=(DL; #=[;\O8+4QUJ3IA:]Y9EY>AO&T MJR4Z@;%"JQQG28H1**Y+H?8Y7BW)RW(VG^/II#=^(F3SNBC0F^;'&I1#,P/, M08E:X2JT+L$>T,[H&JVU.8@3(^2H;)1^P\B%[R[ MX]M!I+/A<$AC](I:\1OHRV9T\UXLHT\BE'5,<<"3'D+GYS!:P@)V*,RKQ?RF M2./X5NB$ZYJ&,)UIWZ0/MH?+\WOU6*0RL,NQQYTW'JRD_6#[^6&"^VP@QU;4 MC?1NZ<]U.)/\*&,W"K__QH/Z_VYV%H+.@2JAC%)C>O,/)KTO4$L#!!0 ( M )N!8E "1N"XH $ -(% 5 <'1C="TR,#(P,#,P,E]D968N>&ULM91? M;_(@%,;O_12LNZ:TFEUHU&5S-R8N>:-9MEL*1TLL8 #7OM]^@'\VLW59G+MI MH3SG.;]S"@QO&UFA5S!6:#5*\C1+$"BFN5"K4?*TP'>+R72:W(X[PRN,7^[G M,_2@V5:"*48[X)0'%1"K0?A45 +J+%B M8%D)DLXTHR[F+IW;# BIZSIM"E.EVJQ(-\MZY!C5J@@S?)#A\ GG7=S+T\;R M!/D*E8VY?Y#D(&\^Z>M>5.?]?I_$U:/4BJ^$WC8G+X^S1:P3"V4=50R2<0>A M73N,KF .2Q3>3_/IB3TL!RE'BY\X6' M4K)N*/NZ-<#]W\ HL4)N*E\M><>AAAV(]L./4,=V">4(%Y+L-816U2E+2X]O MH@4/F-E-1/P0>6DH/P85]C3FL*3;RIV)V.KSA\!:4J%^SWMB5P:M/1^AFT+P,?6G(G[C5,KM-\T0HEPO\W\=*\.7.>=]5T>:!PH#CQF M&I*3FW7<>0-02P,$% @ FX%B4-?\J@:^"P 9&< !4 !P=&-T+3(P M,C P,S R7VQA8BYX;6S5G>UOVS8>Q]_WK]!E;^Z <\/GAV'M0%+D$%RV%DV' M#7WMSG]3]'$SGBW(T'V<'']\ER1)'D<^R+]E94OWY^Y>CO>GD M877$X3P[KWA_SHII/CDI1T5Y/#K-9CY&W=I%D9WM;F)6%!LM5(1D10BRBM / MSS11D9>C6<%6.RZ')_11V-3K/U.FB+$;^'>FD M5=!:)J1V2EE,C(;(:BXH0YJ98=W*,)L/?C]9G[-^Z\E6(2'<4>N U89J (5$ MJ5&6,<)OPXKK(D59CD/^LX__WI\'ON M[@E-5A-]/3^_)JF-(#T1R\<;15+URA=!E0&@N@1V]_,QD'S<%LBR7[-J6907 MJY+:^+VJ8ISDQ20K_')M_4.C8OP,R-41A^/]PWFH4 M\E0[C0Q#5E&CC "6$0L<=!@0RT',0"[WS*Q/C.+[U785)JS>X[D\[<)>D<19 M,(S&HUJN BQ\@OKLBVS\_CS_=N@[Y5- 6;T85"\& *YV##\\[O".(F_,Y'7+ MNWGLO.58B"_I^^50V %1AAJ(JV!S@JH,%N/8>TPBZWMS=:=,PY:ET)H M ;4(2&2XQCCEA&K!M'JI(E^F2GRLI,H57^^1T,(+OS]>#0T0BJI+&6Q >,8* MS8"]'3TTS+_#$VU(A C#SLMI>?$D8C[Y0QP@O2LBV6FY'NHI$H5+HMF MP)YW1>^LXE01B:D+4>PBL,<3K6"]OB;:Q<\[&C2QDCB:C_/B*B_JG>2)WU!F M)K^>E\6=R2=>3=QR9H353"-%D.0,@U4)*$[2X/U#R+F4-H0!!Q1*.864:ZVY M!5H#P:BFP+V,0M1DX@]:_#.I\_D1DWPN\F]3_]N/M4E+LJ%R>3FHC5RS$>\! MU57(I$KY @)ZDM*3/NJ&[UO14T>]V;)5EY3"Y>6FL^RWZ\O3K!A:;A5+-6;> MAI3!E". ZGK2 F)H=)RI'C3,!+(6PQ1RX1M64*26&992Q9SVB[:^KW:8?%Z. MIO-LDE29?#F=Y<7EJICJ=Y8Q8^440R[41#U!:Z2=$#3=V>5[SY]420- ;\4; M3:)O2:)Q_\.-\'5T>S3Q.ZSIV73Y*?IZD&.(L%(&*[]^(D)!OZA?3;>&0 [B M]+#O+,X218BE6@M F82:I@3*^C0< &-?9@GCTR6;\1I*HC',4&.\!,=&^HA' MV)U,]D!YTBQM0;X5S;3NQY9SNB$3+J#5_F'UQ[&?N>$P32TW#',-4RNQI8*G M<+W6IX[S./GL.H,5F)#42$R5HE1I1;Q+4Z(,9#9-==^+E,=[I]6+I J7?)I' M;YT:00R53M_\&@DG'EUWPMD!Y$G9M 'X5D33J@];DFE/)%HPQK_\5'S-;^9# M*A$@PCI"E+(4,^'W6NOI&!CA&NGE0?M*4B@LXWYRMQ0B+9R&B%#$%!?*3_@O M+)K!/)8UI1(ND MOECSJ5A?Y1RF$/M2<%(X(;E?"-'4K_)7!2'\.1O9Y/%)4,J4!4)+B22E4OH3 M4HX%1:HZC3;_;]=ZF[*,E$N?&-L9)IQ@YYIY!"7$-4TYOC'A-.[&/NNTXQ*M MGL_YHAS-_CV]JB\28R6$15P1+9'"5DM([HL%$J@:B6?S%%PP*YP%RF\9J*-" M,H PZU\T&D!#9-"/XQE33 ML!/[1-.&28AFJN63*K)1W3Q4UO@5E$20(T"AI8B;=4EP#$VH6#8:5E2&OI*T]9[KC1OBM]KV#J%7T5)M(<<6">=T5O3.+L$(BC"QD\[/&>\F\$ MY?4+OEGLO.5@""_JZL'(V>>+?+[^$(DJK*$#E&FK3*H4=@:OQF]*_#^$%O96 MPP)Q*9F6U %.E5%*2JB[O.D]2!HC^YB8?T?)'WRB>NT"/0=%'L MCWN^I^ ; WK]HF\>/>]@@(07_Q_%M"RSN^!WMRZQTT #YACF%"CG>\$<5CS5P@KJ1,\:6(5*-E.%JZ A MLN=]T#^M."E$@NI"##L1[+%#.UROKXB6^?.N!DZX+$[RV70\+:?S\U]'OO"F MH]F0,Z YY89Z$7DY4S,[]0P:1ZQEM:PR6$%%C)_(9E/1L2&7S1\8E3(&E4 MBE,G@';4KX$T=WZ7#8A+'06.1#WWW4 //ME@_"!:LLR6U.'"1=&&X?/">"%\ M<>)H1JX+A>S'L4B)*&HMD^D:6,I1HR##6BQI\)&0HYY,0H395\<=TL$W9CG098H]W3 M+]&6!HJ!V8.(MMB$Z:@YTC M3;2 C&JD)<6$^MT!KJ9I*/J^'K(*DRS3A-=]))KGB[X_*I$5'P:DBT+?Z/*> M*F^&Y?5+O&'NO.V B)_C[>WXP@^ K/[B )TB!B&F)-5($JLHA78UD"UT.OCN M\)V-0T)="HT12$AJF=#&%TOU<$;*$/(=Z?O2YRI3L@X5^;4?S8"%3_>]L8J\ M AJ'J7POMXN^8_5MP"+\#TUYFQ;EWT2]%?E->^,W(U6A^ M-T0<.R*U$]SZ]46J"?%HL%_>:/]3(??7&^RLKB> R/ MP'CDBEDYSXK%\?CO\XD\UROGKSVV3RC_IX.HK+VY?6;CZZ MS>KKT:>YJSZ/KGRY''TJ_>?L2SJ9W"N--A=Y5GQ^W7QO9Y.;V]OC]:7/C\J_6** ,#3KUI[)9J_)H]BD^;6!*()AD?K M:CX>A1D6U6;L%PSR*+[>DK_%&VDHA)ANGGX5K;)=@L$LG/[S[O1\,\])5E1U M6LS<^.VKT>@>#E_F[J.[&C7??W\\>6)D5<\NL_)H5BZGS>.I+D.0SM*%>X0_ MC+XQA?INY8['5;9Y\SU8XMZCPBV: M\)^FERY_ZLPNO=S[)VI-E$03)4@W[NZRUK&G[UW=K;//#7;L[YGS63DW1<<0 M[S;;B^_G=>H[QGR?X8[]OP@9T77K^;;)KGTNZS3OV.NIDWBRQI7_ M8Y^7#0A50&&#>^5F1XORRW3NLA S*)J+27,Q ?!A7?T]W$H>4;D( ^UP_[E( M EFLK$*:(B.)EIH#0R,#++081(:!ESC^?2BEGXU*/W<^E"[C47ARY;Q_6$4. M+/:;T-9;O\?4S[8(\53Q06*Z2GUP83*[SO+YHW93^W03M;(3](*O?8;\ZS(2 MAT3Q@]@_D4VLU18:&T-H #$("*29PCAF$5&<*MF"!&C0)&@#8T]L,$6=U7@$7]N@DUD0RB@Q1B@-"!50DCJ! M1C'. -"F!3'H@(G1#9R]LD3.YR$NU<-7V,) A.^03PW$4Q5I@(B4A4LDH M,#Z.I(;4Q+%JDS;8@-G1'LI?P0P=+C_XB_*V> DOODDG4A#(#65$!Z9#I+A5 M$$4$4#/_/EEZSIO[^ &,]4$A13:0!70B!! MB!!26L(P)RA,BFBE6[!##)\=[=#\%10Y*ZLZS?_-5C_1LF#+.;V06./='AO,RS659GQ>)=*%]\EN9[N+ MF%#& M@-&4J@A9@L.F644PI#(&B&"8BE8I89C=RM8@]L2",^\:PXZ2J M;IS_WQS94DL,H316D&*H$-%,2J0)9)!%6BHB12NF#+.%V3&D?:TI;G835KP[ MB"XOLCK?M[5X+I8P$G;'BDO$*"$2<4YY#(FPAB*.A&ES8@Z'V;1L"6%/\;_P M:?-B[?G=\K+<5TX\D4DPL89P%BD.*5$HE,@X(D:'!1!A#'FK2F*8C^ MHUDZOP@L_=.7M_5U6+E6:7%WL/&X4R-A#%&%I!(!$<*,E2K4QQ)0:3%AS,9M M7J4:Q"S1[)8@.:/@T/PD%S/HO=Y@:SV03!J7"H3BFL#F6BX00D4&6-STU M+C5MLV:@838CN\"Q)SK(4,[.FY+6YNEB#PV>R"20LK 9,DP8B@D&7!(-H(X( M@U#'[4H&-,Q^9!O\OH7]S70+NM-PX^VKAP?-1_,?1F]?_0=02P$"% ,4 M" ";@6)0:E:4WU09 "GI@ "P @ $ 83AK,S(R,"YH M=&U02P$"% ,4 " ";@6)0[,\B&-HO !FT0( &@ @ %] M&0 97AH:6)I=#DY,7!R97-S v3.19.3.a.u2
Cover Page Document
Mar. 02, 2020
cover page [Abstract]  
Document Type 8-K
Document Period End Date Mar. 02, 2020
Entity Registrant Name PTC THERAPEUTICS, INC.
Entity Address, State or Province DE
Contained File Information, File Number 001-35969
Entity Tax Identification Number 04-3416587
Entity Address, Address Line One 100 Corporate Court
Entity Address, City or Town South Plainfield,
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07080
City Area Code (908)
Local Phone Number 222-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value per share
Trading Symbol PTCT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001070081
Amendment Flag false
XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Document Sheet http://www.ptcbio.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports a8k3220.htm exhibit991pressrelease.htm ptct-20200302.xsd ptct-20200302_cal.xml ptct-20200302_def.xml ptct-20200302_lab.xml ptct-20200302_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8k3220.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ptct-20200302_cal.xml" ] }, "definitionLink": { "local": [ "ptct-20200302_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "a8k3220.htm" ] }, "labelLink": { "local": [ "ptct-20200302_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ptct-20200302_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ptct-20200302.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ptct", "nsuri": "http://www.ptcbio.com/20200302", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8k3220.htm", "contextRef": "D2020Q1KFiling", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page Document", "role": "http://www.ptcbio.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8k3220.htm", "contextRef": "D2020Q1KFiling", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Contained File Information, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.ptcbio.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "ptct_CoverpageAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "cover page [Abstract]", "label": "cover page [Abstract]" } } }, "localname": "CoverpageAbstract", "nsuri": "http://www.ptcbio.com/20200302", "xbrltype": "stringItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } XML 17 a8k3220_htm.xml IDEA: XBRL DOCUMENT 0001070081 2020-03-02 2020-03-02 false 0001070081 8-K 2020-03-02 PTC THERAPEUTICS, INC. DE 001-35969 04-3416587 100 Corporate Court South Plainfield, NJ 07080 (908) 222-7000 false false false false Common Stock, $0.001 par value per share PTCT NASDAQ false